Tadalafil is a sexual enhancer that was launched on the market for the first time at the end of 2002 and is used to treat erectile dysfunction, since 2010 also to treat pulmonary arterial hypertension and since 2012 to treat benign prostate syndrome.
Tadalafil works similarly to sildenafil (Viagra), vardenafil, and avanafil by blocking the enzyme phosphodiesterase-5 (PDE-5). PDE-5 is responsible for the fact that an erection is broken down so that the tissue of the erectile tissue does not die due to a permanent erection due to insufficient blood flow. By inhibiting PDE-5, sexual stimulation makes erections easier and lasts longer. However, these PDE-5 inhibitors cannot replace sexual stimulation. Erections do not affect the duration of PDE-5 inhibitors. During this time, depending on the man's constitution, several erections and ejaculations can occur. In addition, the active ingredient was given a new indication: Tadalafil has also been prescribed for the treatment of benign prostate syndrome since November 2012 and is reimbursable for this.
In contrast to the other active ingredients, tadalafil can also be taken daily in the low 5 mg dose. This so-called constancy therapy, together with a long duration of action, ensures that the active ingredient remains in the body around the clock and that spontaneous sexual activity is also possible. In the case of the higher doses of 10 mg and 20 mg, daily intake over a longer period is not recommended.